Pharmaceutical Research Co., Ltd. (CEO Shin-kyu Kim, Ki-seok Kang) announces that it has obtained a Japanese patent for a joint cavity injection composition.
It is an invention that relates to a composition for articular cavity injection comprising nucleic acid and chitosan. In the composition, the nucleic acid and chitosan are mixed to improve joint mobility and are believed to be effective in alleviating and improving joint pain disease.
The composition is prepared by a patented technology that does not cause sediment formation and layer separation, thus, is able to produce gel stability and biocompatibility which promotes the intra-articular injection. The patent has already been registered in South Korea and plans to pursue registration in the US and Europe.
“PN (Polynucleotide) joint cavity injection with Conjuran® has established itself as a representative product that is driving our company’s growth,” said an official from Pharma Research. “Based on the patent, we will continue to develop more knee care products.”
On the other hand, PharmaResearch is a regenerative medicine-based pharmaceutical biotech company that manufactures and sells pharmaceuticals, medical devices, cosmetics, and health functional foods, centering on DOT™ PDRN (Polydeoxyribonucleotide) and DOT™ PN, which are tissue regeneration materials. Some of their other products are Rejuran®, Conjuran®, Rejuran Cosmetics, and Re-An® eye drop.
Company Name: Pharma Research Co., Ltd.
Contact Person: Doyoung Kim
Email: Send Email
Country: South Korea